干扰素调节因子-4结合蛋白与癌症的相关研究进展

doi:10.11904/j.issn.1002-3070.2017.01.020

实用肿瘤学杂志 ›› 2017, Vol. 31 ›› Issue (1): 93-96.doi: 10.11904/j.issn.1002-3070.2017.01.020

• 综述 • 上一篇

干扰素调节因子-4结合蛋白与癌症的相关研究进展

侯阳明¹, 徐颖娟² 综述, 崔云甫¹ 审校

1.哈尔滨医科大学附属第二医院普外科(哈尔滨 150086);
2.哈尔滨医科大学附属肿瘤医院妇科

收稿日期:2016-09-30 出版日期:2017-02-28 发布日期:2017-02-20
通讯作者: 崔云甫,E-mail:yfcui777@hotmail.com
作者简介:侯阳明,男,(1991-),硕士研究生,从事普外科肝胆胰的研究

Advances in the tumor related research of IRF-4 binding protein

HOU Yangming¹, XU Yingjuan², CUI Yunfu¹

1.Department of Biliary and Pancreatic Surgery,The Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China;
2.Department of Gynecology,The Affiliated Turmor Hospital of Harbin Medical University

Received:2016-09-30 Online:2017-02-28 Published:2017-02-20

摘要/Abstract

摘要： 干扰素调节因子-4结合蛋白(Interferon regulatory factor-4 binding protein,IBP)是一种微管结合蛋白,早期研究指出其功能主要与免疫系统相关。新近证据指出该蛋白参与调节细胞骨架重构及细胞内信号传导,与部分恶性肿瘤的发生发展密切相关。研究者认为该蛋白可能成为癌症分子治疗的新靶点。本文结合已有的实验研究数据,分析IBP的结构、功能,以及该蛋白在癌症生物学中的多重效应,为进一步的靶向治疗研究提供理论依据。

关键词: IBP, 结构功能, 肿瘤, 作用机制

Abstract: Interferon regulatory factor-4 binding protein(IBP),served as a novel type of microtubule binding protein,is proven to play an important role in the immune system.New evidence suggests that the protein is associated with the occurrence and development of some malignant tumors through the effects of cytoskeletal remodeling and cell conduction mechanism.Therefore researchers believe that IBP may become a new target for cancer molecular therapy.Based on the existing experimental data,this study aims to investigate the structure of IBP,as well as its multiple oncology effects.Furthermore,we provide the theoretical basis for IBP targeted therapy in the treatment of malignant tumors.

Key words: IBP, Structural-function, Tumor, Mechanism

中图分类号:

R730.3

侯阳明, 徐颖娟综述, 崔云甫审校. 干扰素调节因子-4结合蛋白与癌症的相关研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 93-96.

HOU Yangming, XU Yingjuan, CUI Yunfu. Advances in the tumor related research of IRF-4 binding protein[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 93-96.

参考文献

1 Hu CM,Jang SY,Fanzo JC,et al.Modulation of T cell cytokine production by interferon regulatory factor-4[J].J Biol Chem,2002,277(51):49238-49246.
2 Shu CL,Jing YL,Su LC,et al.SWAP-70:a new type of oncogene[J].PLoS One,2013,8(3):e4422.
3 Gupta S,Lee A,Hu C,et al.Molecular cloning of IBP,a SWAP-70 homologous GEF,which is highly expressed in the immune system[J].Hum Immunol,2003,64(4):389-401.
4 Liu JJ,Lin M,Yu JY,et al.Targeting apoptotic and autophagic pathways for cancer therapeutics[J].Cancer Lett,2011,300(2):105-114.
5 Lazer G,Katzav S.Guanine nucleotide exchange factors for RhoGTPases:good therapeutic targets for cancer therapy?[J].Cell Signal,2011,23(23):969-979.
6 Srougi MC,Burridge K.The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage[J].PLoS One,2011,6(2):e17108.
7 Chen Q,Gupta S,Pernis AB.Regulation of TLR4-mediated signaling by IBP/Def6,a novel activator of Rho GTPases[J].J Leukoc Biol,2009,85(3):539-543.
8 Goudevenou K,Martin P,Yeh YJ,et al.Def6 is required for convergent extension movements during zebrafish gastrulation downstream of Wnt5b signaling[J].PLoS One,2011,6(10):e65.
9 Burgess DJ.Breast cancer:circulating and dynamic EMT[J].Nat Rev Cancer,2013,13(3):148-149.
10 Peng L,Zhang Z,Wang Q,et al.The ectopic expression of IFN regulatory factor 4-binding protein is correlated with the malignant behavior of human breast cancer cells[J].Int Immunopharmacol,2009,9(7/8):1002-1009.
11 Yang M,Fang Y,Peng L,et al.Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells[J].Mol Cancer,2011,11(1):1-13.
12 Chen S,Han Q,Wang X,et al.IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway[J].Cell Death Dis,2013,4(10):377-377.
13 杨明珍.乳腺癌中IBP的转录调控机制及其意义的初步研究[D].北京:第三军医大学,2012.
14 Zhang Z,Wang Q,Peng L,et al.Overexpression of the interferon regulatory factor 4-binding protein in human colorectal cancer and its clinical significance[J].Cancer Epidemiol,2009,33(2):130-136.
15 Vistica BP,Shi G,Nugent L,et al.SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis(EAU)[J].Mol Vis,2012,18(192):1858-1864.
16 何颖,张竹君.IBP通过上皮间质转化促进结肠癌细胞迁移和侵袭[J].第三军医大学学报,2016,38(11):1281-1285.
17 Tiwari N,Gheldof A,Tatari M,et al.EMT as the ultimate survival mechanism of cancer cells[J].Semi in Cancer Biol,2012,22(22):194-207.
18 张竹君.特异性IRF-4结合蛋白(IBP)多克隆抗体制备及其在人结肠癌中表达模式的初步研究[D].北京:第三军医大学,2009.
19 Gulhati P,Bowen KA,Liu J,et al.MTORC1 and mTORC2 regulate EMT,motility,and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways[J].Cancer Res,2011,71(9):3246-3256.
20 Chang YJ,Cheng YW,Lin RK,et al.Thrombomodulin influences the survival of patients with non-metastatic colorectal cancer through epithelial-to-mesenchymal transition(EMT)[J].PLoS One,2016,11(8):e0160550.
21 Shuman Moss LA,Jensen-Taubman S,Stetler-Stevenson WG.Matrix metalloproteinases:changing roles in tumor progression and metastasis[J].Am J of Pathol,2012,181(6):1895-1899.
22 简从相,黄晓山,李晨军.IRF-4结合蛋白在口腔鳞癌中的表达及临床意义[J].实用口腔医学杂志,2012,28(4):478-481.
23 潘磊,简从相,李卓,等.IRF-4结合蛋白对口腔鳞癌细胞生长作用的机制研究[J].西南国防医药,2014,24(5):468-470.
24 石俊婷,赵凌,蔡双兵,等.IBP对口腔鳞癌增殖作用的体内研究[J].西南国防医药,2014,24(9):951-953.
25 熊剑,简从相,李鹏,等.IRF-4结合蛋白对人涎腺腺样囊性癌细胞增殖的抑制作用[J].第三军医大学学报,2011,33(6):554-557.
26 熊剑.IBP(IRF-4结合蛋白)在人涎腺腺样囊性癌中表达及功能的实验研究[D].北京:第三军医大学,2011.
27 Ishii K,Shimoda M,Sugiura T,et al.Involvement of epithelial-mesenchymal transition in adenoid cystic carcinoma metastasis[J].Int J Oncol,2011,38(4):921-931.
28 Radisky DC,Levy DD,Littlepage LE,et al.Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability[J].Nature,2005,436(7047):123-127.
29 熊剑,常慧君,李鹏,等.IBP促进人涎腺腺样囊性癌细胞对紫杉醇耐药[J].第三军医大学学报,2012,34(8):723-725.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[4]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[5]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[6]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[7]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[8]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[9]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[10]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	阚钧, 周岱翰综述, 张恩欣审校. 肿瘤合并心血管疾病的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 558-561.
[14]	顾琦晟综述, 李继坤审校. 锰超氧化物歧化酶在肿瘤发生发展过程中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 562-566.
[15]	刘娟综述, 张澍田审校. 细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 575-578.

干扰素调节因子-4结合蛋白与癌症的相关研究进展

Advances in the tumor related research of IRF-4 binding protein

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价